Table 1 Demographic characteristics and clinical outcome variables of randomized participants

MBCT

(n = 62)

HQCT

(n = 62)

WC

(n = 63)

%

%

%

 Male

29.0

32.3

27.0

 Female

71.0

67.7

73.0

 Primary

17.7

14.5

17.5

 Secondary

58.1

48.4

58.7

 Tertiary

24.2

37.1

23.8

MBCT vs. WC

HQCT vs. WC

MBCT vs. HQCT

Χ (SD)

Χ (SD)

Χ (SD)

ES

ES

ES

Age

51.6 (9.5)

50.7 (10.6)

49.2 (12.4)

DASS-21 (T0)

33.4 (12.2)

34.8 (12.7)

33.1 (14.3)

DASS-21 (T1)

28.8 (11.7)

27.2 (11.6)

32.1 (14.2)

−0.27^a

−0.49^a

0.24^a

DASS-21 (T2)

27.2 (11.4)

26.2 (10.8)

31.3 (13.0)

−0.33^b

−0.5^b

0.19^b

SF12_Phy (T0)

12.6 (2.4)

12.6 (2.6)

12.7 (2.7)

SF12_Phy (T1)

12.9 (2.5)

13.2 (2.7)

12.4 (2.6)

0.23^a

0.34^a

−0.12^a

SF12_Phy (T2)

12.9 (2.4)

13.9 (2.5)

12.3 (2.6)

0.27^b

0.64^b

−0.40^b

SF12_Men (T0)

15.9 (3.5)

15.5 (3.5)

15.4 (3.2)

SF12_Men (T1)

17.3 (3.5)

16.3 (3.3)

15.7 (3.2)

0.33^a

0.15^a

0.17^a

SF12_Men (T2)

17.7 (3.5)

16.5 (3.2)

15.3 (3.1)

0.56^b

0.33^b

0.23^b

CPSS (T0)

20.2 (6.4)

22.9 (6.4)

23.0 (5.6)

CPSS (T1)

18.0 (6.2)

22.7 (6.5)

23.1 (5.3)

−0.38^a

−0.05^a

0.21^a

CPSS (T2)

17.9 (6.6)

20.6 (6.2)

22.7 (5.5)

−0.33^b

−0.33^b

0.00^b

PSQI (T0)

10.9 (4.1)

10.6 (3.8)

11.1 (4.6)

PSQI (T1)

10.0 (3.4)

9.8 (3.3)

11.3 (5.0)

−0.25^a

−0.24^a

−0.03^a

PSQI (T2)

9.9 (3.5)

9.8 (3.5)

11.5 (4.7)

−0.32^b

−0.28^b

− 0.05^b

GSE (T0)

21.0 (6.0)

22.3 (6.1)

21.8 (6.5)

GSE (T1)

21.6 (6.4)

23.5 (5.4)

21.7 (5.8)

0.11^a

0.21^a

−0.10^a

GSE (T2)

21.6 (6.3)

23.7 (5.9)

21.5 (6.5)

0.14^b

0.27^b

−0.13^b